Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Somapacitan · Sogroya

Recombinant protein · Agonist of growth hormone receptor (GHR) · developed by Novo Nordisk

Approved FDA, Aug 2020
NVO Developer
1 Registered trials

What is Somapacitan?

Somapacitan is a long-acting human growth hormone analog that binds the dimeric growth hormone receptor on target cells, triggering intracellular signal transduction, including IGF-1 production in the liver. It is given once weekly by subcutaneous injection and is studied in pediatric growth disorders, including growth hormone deficiency in children.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Sogroya
Drug type
Recombinant protein
Targets
growth hormone receptor (GHR)
Mechanism
Agonist of growth hormone receptor (GHR)
Pathways
IGF-1 production in the liver, GH receptor signal transduction
Therapy area
Endocrine
Developer
Novo Nordisk Inc (NVO)
FDA status
Approved as Sogroya (August 28, 2020), BLA761156 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Feb 25, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03811535 Phase 3 Growth Hormone Deficiency in Children Completed NVO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Growth Hormone Deficiency in Children

Other drugs acting on GHR

More from Novo Nordisk

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the NVO page.

Follow NVO, the company behind Somapacitan

See NVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.